Press Release: GBT : GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced its support for the Sickle Cell Disease Treatment Centers...
Read full article »
GBT is a California-based biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of sickle cell diseases.
Read more